Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineagesJean‐François Emile, Lawrence M. Weiss, Oussama Abla et al.|Blood|2016Cited by 1.6k
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> MutationsFilip Jankú, Razelle Kurzrock|Journal of Clinical Oncology|2012Cited by 451
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, Manish R. Patel et al.|Cancer Discovery|2017Cited by 418
Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular eraGaurav Goyal, Eli L. Diamond, Mark Heaney et al.|Blood|2020Cited by 397
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid TumorsPhilippe L. Bédard, Cristiana Sessa, Josep Tabernero et al.|Clinical Cancer Research|2014Cited by 326